Back to top

AstraZeneca’s CHRONICLES COPD Study Completion: What It Means for AZN Investors

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. The CHRONICLES COPD study, officially titled “Chronicling the COPD Patient...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

AstraZeneca PLC (AZN)